Literature DB >> 28239786

Incidence of Myelofibrosis in Chronic Myeloid Leukemia, Multiple Myeloma, and Chronic Lymphoid Leukemia during Various Phases of Diseases.

T Yu Dolgikh1, N P Domnikova2, Yu V Tornuev2, E V Vinogradova2, Yu M Krinitsyna2.   

Abstract

Pathomorphological study of trephinobiopsy specimens from 129 patients with lymphoproliferative and myeloproliferative diseases was carried out over the course of chemotherapy. Combinations of initial and manifest myelofibrosis (loose network of reticulin fibers and extensive network of reticulin and collagen fibers, respectively) predominated at the debut of chronic myeloid leukemia, chronic lymphoid leukemia, and multiple myeloma. Manifest myelofibrosis was detected in patients with chronic myeloid leukemia without hematological response (failure of normalization of hematological values) and in patients with progressing and relapsing multiple myeloma. Combinations of foci of initial and manifest myelofibrosis were most incident in patients with progressing and relapsing chronic lymphoid leukemia. The incidence of myelofibrosis was higher in patients with multiple myeloma and chronic lymphoid leukemia progression and relapses and in patients with chronic myeloid leukemia without hematological response than at the disease debut and in case of response to chemotherapy. The response to chemotherapy in patients with chronic myeloid leukemia and chronic lymphoid leukemia was associated with a decrease in the incidence of myelofibrosis. In patients with multiple myeloma responding to chemotherapy, the incidence of myelofibrosis did not change in comparison with the disease debut.

Entities:  

Keywords:  chronic lymphoid leukemia; chronic myeloid leukemia; multiple myeloma; myelofibrosis; trephinobiopsy specimens

Mesh:

Year:  2017        PMID: 28239786     DOI: 10.1007/s10517-017-3645-x

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  1 in total

1.  The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors.

Authors:  Barry Paul; Yue Zhao; Gavin Loitsch; Daniel Feinberg; Parker Mathews; Ian Barak; Megan Dupuis; Zhiguo Li; Lindsay Rein; Endi Wang; Yubin Kang
Journal:  Cancer Med       Date:  2020-07-06       Impact factor: 4.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.